Abstract Library

#4535 Survival and toxicity outcomes of somatostatin analogues vs. other systemic therapies as first-line palliative treatment for patients with extrapulmonary G2 well-differentiated neuroendocrine tumours with a Ki-67 index between 10% and 20%

Introduction: In patients (pts) with an advanced well-differentiated (WD-NET) with a Ki-67>10% and ≤20% (“G2 high”), chemotherapy (ChT) or targeted therapies are the preferred first-line palliative options. Somatostatin analogues (SSAs) may offer an alternative, yet randomised evidence is lacking.

Conference:

Presenting Author:

Authors: Dawoodji A, Nuttall C, Eyong M, Farrell K, Barratt N,

Keywords: somatostatin analogue, SSA, non-SSA, Grade 2 well-differentiated neuroendocrine tumour, WD-NET,

#3494 Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumors

Introduction: Lutetium Peptide Receptor Radio Nuclide Therapy (Lu-PRRT) is an effective treatment for progressive, metastatic, somatostatin-receptor-positive, well-differentiated Neuroendocrine Tumors (WD-NETs). It is generally well tolerated.

Conference:

Presenting Author:

Authors: Almeamar H, Cullen L, Murphy D, Crowley R, Skehan S,

Keywords: prrt, neuroendocrine tumor, efficacy, safety,

#3140 Prognostic value of whole-body PET volumetric parameters extracted from 68Ga-DOTATOC PET/CT in well-differentiated neuroendocrine tumors

Introduction: Functional imaging could have a key role as prognostic biomarker in well-differentiated neuroendocrine tumors (WD-NETs).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Thuillier P

Authors: Thuillier P, Liberini V, Grimaldi S, Rampado O, Gallio E,

Keywords: neuroendocrine tumor, 68Ga-DOTATOC PET/CT, tumor burden, prognosis, somatostatin receptor expressing tumor volume, total lesion somatostatin receptor expression,

#2248 High Grade (G3) Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Should the New WHO Classification Apply to All?

Introduction: Grade 3 (G3) neuroendocrine neoplasms (NEN), arising from the gastro-entero-pancreatic system (GEP), are classified according to WHO 2010 and defined as having a Ki67 of > 20%. However this groups together G3 well differentiated neuroendocrine tumours (WD-NET) with poorly differentiated neuroendocrine carcinomas (PD-NEC). Recently, WHO have proposed a new classification for pancreatic NEN, with sub-division into G3 WD-NET and G3 PD-NEC

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Furnace M

Authors: Furnace M, Muller G, Rundell C, Shah R, Luong T,

Keywords: G3, well-differentiated, poorly differentiated, Ki-67,

#2133 Clinicopathological Features of the High Grade Pancreatic Neuroendocrine Neoplasms

Introduction: The high grade pancreatic neuroendocrine neoplasms (PanNENs) include well-differentiated tumors (WD-NETs) with elevated proliferation and poorly differentiated carcinomas (PD-NECs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Delektorskaya V, Solovieva O, Koslov N, Patyutko Y,

Keywords: neuroendocrine, pancreas, neoplasm, grade, survival,